Concord Biotech has received an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at its API facility at Dholka. The said inspection was conducted from April 28, 2025 till May 02, 2025. The USFDA has officially concluded its inspection. This closure indicates that no regulatory action is required, and the facility is permitted to continue its operations without any restrictions.
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1672.45 |
| Dr. Reddys Lab | 1223.60 |
| Cipla | 1230.40 |
| Zydus Lifesciences | 929.00 |
| Lupin | 2331.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: